Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17631454 | 0.93 | AAK1 (0.46) | USP30GPR119AAK1PDE4BTBK1 | |
| SCHEMBL17645008 | 0.91 | AAK1 (0.45) | USP30GPR119AAK1PDE4BTBK1 | |
| SCHEMBL38660667 | 0.90 | PDE4B (0.47) | USP30GPR119PDE4BTBK1 | |
| SCHEMBL2274860 | 0.86 | GPR119 (0.40) | GPR119PDE4BTBK1 | |
| SCHEMBL18348317 | 0.85 | TBK1 (0.52) | USP30GPR119AAK1PDE4BTBK1 | |
| SCHEMBL2276050 | 0.83 | USP30 (0.47) | USP30PDE4BRORC | |
| SCHEMBL24049588 | 0.82 | USP30 (0.54) | USP30GPR119PDE4BRORC | |
| SCHEMBL2269383 | 0.82 | USP30 (0.47) | USP30PDE4BRORC | |
| SCHEMBL2276593 | 0.82 | PDE4B (0.57) | USP30PDE4B | |
| SCHEMBL2575862 | 0.82 | PDE4B (0.53) | USP30PDE4BRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957059-B2 | Modulators of serotonin receptors | JANSSEN PHARMACEUTICA NV (BG) | 2015-02-17 | — | — | US | disclosed |
| US-20140038934-A1 | MODULATORS OF SEROTONIN RECEPTORS | JANSSEN PHARMACEUTICA NV (US) | 2014-02-06 | — | — | US | disclosed |
| US-8575364-B2 | Modulators of serotonin receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-05 | — | — | US | disclosed |
| US-20110207709-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | disclosed |
| WO-2010059390-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038934-A1 | MODULATORS OF SEROTONIN RECEPTORS | HTR1A, HTR2A, HTR6 | USP30 2632/4885GPR119 45/4885AAK1 2935/4885 |
| US-20110207709-A1 | MODULATORS OF SEROTONIN RECEPTOR | HTR1A, HTR6, HTR2A | USP30 2765/4885GPR119 48/4885AAK1 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.